| abstract |
Liposomal compositions comprising peptide epoxyketone compounds are described, as well as methods of making and using such liposomal compositions. These liposomal compositions provide prolonged drug exposure (relative to non-liposomal compositions comprising peptide epoxyketone compounds) without significantly affecting biodistribution of the drug. Tolerability of peptide epoxyketone compounds was also enhanced when formulated in the liposomal compositions. |